OraSure Technologies (OSUR) Scheduled to Post Quarterly Earnings on Wednesday

OraSure Technologies (NASDAQ:OSUR - Get Free Report) is set to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. OraSure Technologies has set its Q3 2024 guidance at EPS.Parties that are interested in participating in the company's conference call can do so using this link.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter. The business had revenue of $54.34 million during the quarter, compared to analyst estimates of $53.35 million. OraSure Technologies had a net margin of 9.88% and a return on equity of 9.15%. On average, analysts expect OraSure Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OraSure Technologies Price Performance

NASDAQ:OSUR traded down $0.06 during trading hours on Wednesday, reaching $4.20. The company's stock had a trading volume of 392,510 shares, compared to its average volume of 904,178. OraSure Technologies has a one year low of $3.91 and a one year high of $8.45. The business's 50-day moving average is $4.24 and its 200-day moving average is $4.50. The company has a market cap of $313.19 million, a price-to-earnings ratio of 11.83 and a beta of 0.05.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on OSUR shares. Evercore ISI increased their price objective on OraSure Technologies from $4.50 to $5.00 and gave the company an "in-line" rating in a report on Wednesday, August 7th. StockNews.com raised OraSure Technologies from a "hold" rating to a "buy" rating in a research report on Friday, October 4th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.67.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.